North America Immunoassay For Neurological Biomarkers Market Size & Outlook
Related Markets
North America immunoassay for neurological biomarkers market highlights
- The North America immunoassay for neurological biomarkers market generated a revenue of USD 3,343.5 million in 2023.
- The market is expected to grow at a CAGR of 12.6% from 2024 to 2030.
- In terms of segment, alzheimer's disease was the largest revenue generating application in 2023.
- Alzheimer's Disease is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 3,343.5 million |
| Market revenue in 2030 | USD 7,683.0 million |
| Growth rate | 12.6% (CAGR from 2023 to 2030) |
| Largest segment | Alzheimer's disease |
| Fastest growing segment | Alzheimer's Disease |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
| Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
Other key industry trends
- In terms of revenue, North America region accounted for 41.5% of the global immunoassay for neurological biomarkers market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,876.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Immunoassay For Neurological Biomarkers Market Scope
Immunoassay For Neurological Biomarkers Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Nimble Therapeutics | View profile | 11-50 | Madison, Wisconsin, United States, North America | https://www.nimbletherapeutics.com/ |
| Sysmex Corp | View profile | 10448 | 1-5-1 Wakinohara-Kaigandori, Chuo-ku, Hyogo Prefecture, Kobe, Japan, 6510073 | http://www.sysmex.co.jp |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Bio-Rad Laboratories Inc | View profile | 8030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | https://www.bio-rad.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
North America immunoassay for neurological biomarkers market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.84% in 2023. Horizon Databook has segmented the North America immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
Increase in funding for neurological biomarker research is expected to drive the market in North America. Furthermore, growing R&D expenditure, advanced healthcare infrastructure, and large number of pharmaceutical companies are boosting the market in North America.
Supportive government initiatives, such as collaborations between the U.S. and Brazil on biomedical research to accelerate R&D in the diagnosis and treatment of chronic diseases, are aiding the market growth.
Poor reimbursement structure for biomarker testing may hinder market growth. Political instability and the U.S.-China trade war may act as threats for the market.
Reasons to subscribe to North America immunoassay for neurological biomarkers market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America immunoassay for neurological biomarkers market databook
-
Our clientele includes a mix of immunoassay for neurological biomarkers market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America immunoassay for neurological biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into North America immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America immunoassay for neurological biomarkers market size, by country, 2018-2030 (US$M)
North America Immunoassay For Neurological Biomarkers Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
